Key Drivers
- Strong gross margin
- Persistent cash burn
- Extreme leverage
AIAI Summary
SNDX has evolved into a commercial-stage growth story with strong Revuforj/Niktimvo traction and 96% gross margins, but the investment hinges on whether revenue scales fast enough to offset persistent cash burn and ~$589M of debt before financing pressure constrains upside.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong gross margin
- •Persistent cash burn
- •Extreme leverage
SNDX offers strong margins and liquidity but remains high-risk due to persistent cash burn, extreme leverage, shrinking equity, and debt-funded operations.
Price Behavior
Key Price Behavior Insights:
- •Lower highs
- •Key support
- •Weak momentum
SNDX remains in a last-month downtrend, with $17.28–$17.62 support critical—hold for a rebound potential, but a break lower signals further weakness.
Sharp decline from $20.78 on 2026-09-02 to $17.28 on 2026-09-16
Sentiment & News
Key News Insights:
- •BlackRock Stake
- •Citi Upside
- •Investor Outreach
BlackRock's 10.18% stake and Citi's bullish target boost Syndax visibility, though no new clinical or regulatory catalysts emerged.
Increased institutional and analyst attention is supportive for sentiment, but near-term performance remains dependent on future clinical and regulatory catalysts
Similar Companies in Healthcare
Other companies in the same sector with AI ratings